PR Newswire Clinical TrialsOriginal article
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Phase 3setidegrasibdocetaxelPositive
AI Analysis
Summary
Astellas dosed the first patient in a Phase 3 study evaluating setidegrasib, a KRAS G12D-targeted protein degrader, versus docetaxel in previously treated advanced non-small cell lung cancer patients. This marks the second Phase 3 study of setidegrasib initiated within six months.
Clinical Trial Data
Phase
Phase 3
Outcome Details
First patient dosed in Phase 3 study of setidegrasib versus docetaxel
Importance:6/10
Sentiment:
0.50
KRAS G12Dprotein degraderNSCLConcologydrug development
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 23, 2026 11:30 PM